1 Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
2 Department of Master's Program in Neurology, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
3 Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
4 Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
5 Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan, China;
6 Faculty of Medicine, “National Yang-Ming University Schools of Medicine”, Taipei 112, Taiwan, China;
7 Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei 112, Taiwan, China
Is the role of the angiotensin-converting enzyme gene in Alzheimer's disease independent of hypertension?
1 Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
2 Department of Master's Program in Neurology, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
3 Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
4 Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan, China;
5 Department of Neurology, Linkou Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan, China;
6 Faculty of Medicine, “National Yang-Ming University Schools of Medicine”, Taipei 112, Taiwan, China;
7 Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei 112, Taiwan, China
摘要 Objective: Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphisms are considered biomarkers of late-onset Alzheimer's disease (AD).However,the results of studies of these polymorphisms have been inconsistent.The ACE protein directly degrades beta-amyloid and thereby slows the progression of AD and its onset.However,it also activates the renin-angiotensin-aldosterone system,which can contribute to hypertension and/or cardiovascular events that increase the risk for developing AD. Methods: In this study,we examined the bidirectional association of the ACE gene and AD in patients with AD with and without hypertension. Results: Patients who were clinically diagnosed with AD (n=983) underwent ACE I/D genotyping.The distribution of the ACE I/D genotypes (P=0.355 for I/I vs.D/D;P=0.888 for I/D vs.D/D) and I alleles (P=0.895) did not significantly differ between hypertensive patients with AD and patients with AD without hypertension. Conclusions: In contrast to traditional theories,the results of this study suggested that the contribution of the ACE gene to the development of AD was not associated with hypertension and similar cardiovascular effects.
Abstract: Objective: Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphisms are considered biomarkers of late-onset Alzheimer's disease (AD).However,the results of studies of these polymorphisms have been inconsistent.The ACE protein directly degrades beta-amyloid and thereby slows the progression of AD and its onset.However,it also activates the renin-angiotensin-aldosterone system,which can contribute to hypertension and/or cardiovascular events that increase the risk for developing AD. Methods: In this study,we examined the bidirectional association of the ACE gene and AD in patients with AD with and without hypertension. Results: Patients who were clinically diagnosed with AD (n=983) underwent ACE I/D genotyping.The distribution of the ACE I/D genotypes (P=0.355 for I/I vs.D/D;P=0.888 for I/D vs.D/D) and I alleles (P=0.895) did not significantly differ between hypertensive patients with AD and patients with AD without hypertension. Conclusions: In contrast to traditional theories,the results of this study suggested that the contribution of the ACE gene to the development of AD was not associated with hypertension and similar cardiovascular effects.
Yuanhan Yang, Shyhjong Wu, Chinchun Huang, Jongling Fuh, Chingkuan Liu. Is the role of the angiotensin-converting enzyme gene in Alzheimer's disease independent of hypertension?[J]. 临床转化神经科学, 2017, 3(2): 97-103.
Yuanhan Yang, Shyhjong Wu, Chinchun Huang, Jongling Fuh, Chingkuan Liu. Is the role of the angiotensin-converting enzyme gene in Alzheimer's disease independent of hypertension?. Translational Neuroscience and Clinics, 2017, 3(2): 97-103.
20170712151018 Table 1 Demographic characteristics of the patients with Alzheimer’s disease.
20170712151026 Table 2 Demographic characteristic of the patients with Alzheimer’s disease with hypertension or without hypertension.
20170712151034 Table 3 The results of the logistic regression after adjusting for the covariables* in the patients with Alzheimer’s disease with and without hypertension.
[1]
Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, Scheltens P, Kehoe PG, Muller M. The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimers Res Ther 2014, 6(3):27.
[2]
Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999, 21(1):71-72.
[3]
Wang XB, Cui NH, Gao JJ, Qiu XP, Yang N, Zheng F. Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease:A meta-analysis. J Neural Transm (Vienna) 2015, 122(2):211-224.
[4]
Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005, 162(4):305-317.
[5]
Meng Y, Baldwin CT, Bowirrat A, Waraska K, Inzelberg R, Friedland RP, Farrer LA. Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community. Am J Hum Genet 2006, 78(5):871-877.
[6]
Yang YH, Lai CL, Tyan YC, Chou MC, Wang LC, Yang MH, Liu CK. Angiotensin-converting enzyme gene and plasma protein level in Alzheimer's disease in Taiwanese. Age Ageing 2011, 40(2):238-242.
[7]
Cosenso-Martin LN, Vaz-de-Melo RO, Pereira LR, Cesarino CB, Yugar-Toledo JC, Cipullo JP, de Souza Pinhel MA, Souza DR, Vilela-Martin JF. Angiotensin-converting enzyme insertion/deletion polymorphism, 24-h blood pressure profile and left ventricular hypertrophy in hypertensive individuals:a cross-sectional study. Eur J Med Res 2015:20-74.
[8]
Ma R, Li X, Su G, Hong Y, Wu X, Wang J, Zhao Z, Song Y, Ma S. Angiotensin-converting enzyme insertion/deletion gene polymorphisms associated with risk of atrial fibrillation:A meta-analysis of 23 case-control studies. J Renin Angiotensin Aldosterone Syst 2015, 16(4):793-800.
[9]
Sahin S, Ceyhan K, Benli I, Ozyurt H, Naseri E, Tumuklu MM, Aydogan L, Elalmis AO, Ozugurlu AF, Onalan O. Traditional risk factors and angiotensin-converting enzyme insertion/deletion gene polymorphism in coronary artery disease. Genet Mol Res 2015, 14(1):2063-2068.
[10]
Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217(4558):408-414.
[11]
Wang DS, Dickson DW, Malter JS. beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006, 2006(3):58406.
[12]
Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H. The N-terminal active centre of human angiotensinconverting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005, 21(3):733-740.
[13]
Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensinconverting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001, 276(51):47863-47868.
[14]
Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005, 280(45):37644-37650.
[15]
Hanon O, Forette F. Prevention of dementia:Lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004, 226(1-2):71-74.
[16]
Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163(9):1069-1075.
[17]
Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007, 6(4):373-378.
[18]
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278(16):1349-1356.
[19]
Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Stopford C, Julien C, Thompson J, Payton A, PickeringBrown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DMA. Apolipoprotein E ε4 allele frequency and age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord 2007, 23(1):60-66.
[20]
Resnick SM, Bilgel M, Moghekar A, An Y, Cai Q, Wang MC, Thambisetty M, Prince JL, Zhou Y, Soldan A, Wong DF, O'Brien RJ, Ferrucci L, Albert MS. Changes in Aβbiomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging 2015, 36(8):2333-2339.
[21]
Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer's disease:Examination of the effect of APOE genotype. J Int NeuropsycholSoc 2002, 8(7):943-955.
[22]
Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning:A meta-analysis. Neurobiol Aging 2011, 32(1):63-74.
[23]
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease:Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
[24]
Folstein MF, Folstein SE, McHugh PR, ""Mini-mental state"". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12(3):189-198.
[25]
Morris JC. The Clinical Dementia Rating (CDR):Current version and scoring rules. Neurology 1993, 43(11):2412-2414.
[26]
Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992, 20(6):1433.
[27]
Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995, 332(11):706-711.
[28]
Wu SJ, Hsieh TJ, Kuo MC, Tsai ML, Tsai KL, Chen CH, Yang YH. Functional regulation of Alu element of human angiotensin-converting enzyme gene in neuron cells. Neurobiol Aging 2013, 34(7):e1921-1927.
[29]
Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006, 98(9):1123-1133.
[30]
Song SB, Jin HS, Hong KW, Lim JE, Moon JY, Jeong KH, Ihm CG, Lee TW, Oh B, Lee SH. Association between renin-angiotensin-aldosterone system-related genes and blood pressure in a Korean population. Blood Press 2011, 20(4):204-210.
[31]
Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene:Its potential as a functional candidate for cardiovascular disease. Clin Sci (Lond) 2013, 124(2):65-76.
[32]
Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia:the Honolulu-Asia aging study. Neurobiol Aging 2000, 21(1):49-55.
[33]
Yang YH, Roe CM, Morris JC. Relationship between latelife hypertension, blood pressure, and Alzheimer's disease. Am J Alzheimers Dis Other Demen 2011, 26(6):457-462.
2017, Vol. 3 
